On Tuesday, Shares of The Coca-Cola Company (NYSE:KO), lost -0.12% to $41.30.
The Coca-Cola Company declared that James Quincey, President and Chief Operating Officer, will present at 11:15 a.m. EDT, Wednesday, Sept. 9, 2015 during the Barclays Global Consumer Staples Conference being held in Boston.
The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages comprise nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters.
Shares of The Blackstone Group L.P. (NYSE:BX), declined -2.99% to $37.28, during its last trading session.
Wall Street landlords bought thousands of homes and sold stock to the public before they’d even filled many of the properties with renters. Now those companies are struggling to persuade investors they can operate efficient businesses, according to Bloomberg.
Shares of the four publicly traded U.S. home-rental firms are below their 2012 to 2013 initial offering prices and have fallen as much as 5 percent in the past month. The companies are learning to operate at the same time they’re trying to please investors, unlike landlords backed by Blackstone Group LP, Colony Capital Inc. and Goldman Sachs Group Inc. alumnus Don Mullen, which haven’t turned to equity markets for capital. Bloomberg Reports
Blackstone, with almost 50,000 houses, has indicated it’s in no rush to take Invitation Homes public as a real estate investment trust. Jonathan Gray, head of real estate at the New York-based firm, said in April that “at some point in the next 12 or 24 months, we’ll have a business that can come public.” Bartling declined to comment on any IPO plans. Bloomberg added.
The Blackstone Group L.P. is a publicly owned investment manager. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations.
Finally, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ended its last trade with -5.88% loss, and closed at $1.60.
AVEO Pharmaceuticals stated financial results for the second quarter ended June 30, 2015.
Second Quarter 2015 Financial Highlights
- AVEO ended Q2 2015 with $26.8 million in cash and cash equivalents.
- Total partnership revenue was about $0.1 million contrast with $1.8 million for Q2 2014. The decrease was primarily due to an additional $1.8 million in revenue recognized in connection with our agreement with Astellas, which concluded in August 2014.
- Research and development (R&D) expense was $1.8 million contrast with $9.3 million for Q2 2014. The decrease in R&D expense was primarily due to a reduction in personnel-related expenses following our January 2015 planned restructuring, the reduction of our leased facilities, in addition to a decrease in external clinical trial and consulting costs associated with the reduced tivozanib clinical development activity and AV-380 preclinical development activity.
- Net loss for Q2 2015 was $5.5 million, or a loss of $0.10 per basic and diluted net loss per share contrast with net loss of $18.0 million or a loss of $0.35 per basic and diluted net loss per share for Q2 2014.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
